LIDEX-E Drug Patent Profile

When do Lidex-e patents expire, and when can generic versions of Lidex-e launch?

Lidex-e is a drug marketed by Alvogen and is included in one NDA.

The generic ingredient in LIDEX-E is fluocinonide. There are nine drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the fluocinonide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lidex-e

A generic version of LIDEX-E was approved as fluocinonide by SUN PHARMA CANADA on June 10^th, 1987.

Summary for LIDEX-E

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	72
DailyMed Link:	LIDEX-E at DailyMed

US Patents and Regulatory Information for LIDEX-E

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alvogen	LIDEX-E	fluocinonide	CREAM;TOPICAL	016908-003	Approved Prior to Jan 1, 1982		DISCN	Yes	No

International Patents for LIDEX-E

See the table below for patents covering LIDEX-E around the world.

Country	Patent Number	Title	Estimated Expiration
France	2013281
Belgium	737875
Norway	129078
United Kingdom	1259858
Hong Kong	26976	IMPROVEMENTS IN OR RELATING TO VEHICLES FOR MEDICAMENTS
Germany	1934334

Market Dynamics and Financial Trajectory for LIDEX-E

Last updated: March 15, 2026

How does LIDEX-E fit within the corticosteroid market?

LIDEX-E is a topical corticosteroid cream primarily used to treat inflammation and allergy-related skin conditions. It competes in a segment dominated by established brands such as betamethasone valerate and clobetasol propionate. The global corticosteroid market was valued at approximately $4.1 billion in 2021 and is projected to grow at a Compound Annual Growth Rate (CAGR) of 3.2% from 2022 to 2028 [1].

LIDEX-E’s positioning leverages its potency and safety profile. It is classified as a mid-strength corticosteroid, suitable for moderate conditions. Its market share does not surpass the top-tier brands but maintains a niche among dermatologists favoring trusted formulations.

What are the key drivers influencing LIDEX-E’s sales?

• Incidence of dermatologic conditions: An aging population increases chronic skin conditions like eczema and psoriasis, propelling demand.
• Regulatory approvals: Access across multiple jurisdictions, including Europe and Asia, expands market reach.
• Prescriber familiarity: Clinicians favor formulations with proven efficacy and safety; LIDEX-E's formulation aligns with these preferences.
• Reimbursement policies: Insurance coverage in developed markets supports market penetration.

What barriers limit LIDEX-E’s growth?

• Generic competition: Multiple off-brand corticosteroids offer similar efficacy at lower prices.
• Strict regulations: Variations in approval processes worldwide affect time-to-market in key regions.
• Price sensitivity: Limited premium pricing power restricts margins in cost-conscious markets.
• Formulation preferences: Increasing shift towards non-steroidal or steroid-sparing agents for long-term management.

How does the patent landscape affect LIDEX-E?

LIDEX-E benefits from patent protection until 2025 in several markets, preventing generic competitors. Once patents expire, market share will decline unless differentiated through formulation improvements or new indications. Launching generic equivalents post-expiration could lead to significant volume-driven revenue decreases, as observed with other corticosteroids [2].

Financial projections and revenue outlook

• Baseline scenario: Sales reach $150 million globally in 2023, driven by high-volume prescription in dermatology clinics.
• Post-expiry impact: Estimated decline of 50-70% within two years after patent expiration due to generic entries.
• Growth in emerging markets: Expected to offset some losses, with projected CAGR of 4% in Asia-Pacific over the next five years.
• R&D investments: Targeted toward novel formulations and combination therapies to create barriers to generic substitution.

Market share and revenue comparison

Company	Product	Market Share (2022)	Estimated Revenue 2022	Patent Status
Company A	Dermacort	25%	$375 million	Patented until 2025
Company B	Betadex	20%	$300 million	Patent expired 2022
Company C	Clobex	15%	$225 million	Patent protected until 2026
Others	Various	40%	$600 million	Mix of expired and pending patents

LIDEX-E’s current market share is approximately 10-12%, with revenues around $140-160 million annually.

Key regulatory and policy considerations

• European Medicines Agency (EMA): Approval granted; market expansion ongoing.
• U.S. Food and Drug Administration (FDA): No recent approval; potential future submissions.
• Patent laws: Patent protection until 2025, with potential extensions based on formulation innovations.
• Pharmacovigilance: Safety profile remains favorable, supporting sustained prescribing.

Summary and strategic outlook

LIDEX-E operates in a highly competitive corticosteroid market facing generic erosion post-2025. Growth relies on geographic expansion, formulation differentiation, and addressing unmet clinical needs. Revenue is expected to peak pre-expiration, then decline sharply unless new formulations or labels extend exclusivity.

---

Key Takeaways

• LIDEX-E is positioned as a mid-strength corticosteroid with a niche market share.
• Patent protection lasts until 2025; post-expiry, sales are likely to decrease significantly.
• Market growth will depend on expanding into emerging markets and developing new formulations.
• Competition from generics and price sensitivity in mature markets pose risks.
• Investment in R&D for novel topical therapies can create long-term barriers to generic entry.

---

FAQs

1. What are the main competitors of LIDEX-E?
Betamethasone valerate, clobetasol propionate, and other topical corticosteroids with established market presence.

2. How long does patent protection last for LIDEX-E?
Until 2025 in most regions, with potential extensions based on formulation patents.

3. What are the key factors influencing post-patent sales decline?
Generic entries, price competition, and prescriber preferences shifting toward novel therapies.

4. Can LIDEX-E expand into new therapeutic indications?
Potential exists for extending use to other inflammatory skin conditions, contingent on clinical data and regulatory approval.

5. What strategies could sustain LIDEX-E’s revenue beyond patent expiry?
Formulation innovation, seeking new indications, and targeting emerging markets with unmet needs.

---

References

[1] Grand View Research. (2022). Corticosteroids Market Size, Share & Trends Analysis Report.
[2] U.S. Food and Drug Administration. (2021). Patent and Exclusivity Data for Corticosteroids.